Rigel Pharmaceuticals RIGL Contract revenues from collaborations — Revenue recognized
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rigel Pharmaceuticals's contract revenues from collaborations — revenue recognized.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rigel Pharmaceuticals's contract revenues from collaborations — revenue recognized?
- Rigel Pharmaceuticals (RIGL) reported contract revenues from collaborations — revenue recognized of $3.9M in Q1 2026.
- How has Rigel Pharmaceuticals's contract revenues from collaborations — revenue recognized changed year-over-year?
- Rigel Pharmaceuticals's contract revenues from collaborations — revenue recognized decreased by 60.2% year-over-year, from $9.78M to $3.9M.
- What is the long-term trend for Rigel Pharmaceuticals's contract revenues from collaborations — revenue recognized?
- Over 4 years (2021 to 2025), Rigel Pharmaceuticals's contract revenues from collaborations — revenue recognized has grown at a -4.9% compound annual growth rate (CAGR), from $75.73M to $62.03M.
- What does contract revenues from collaborations — revenue recognized mean?
- This metric represents the revenue recognized from strategic partnerships and licensing agreements where the company grants rights to its intellectual property or drug candidates to third-party collaborators. It typically includes milestone payments, upfront fees, and royalty streams generated as partners advance the development or commercialization of the licensed assets. This revenue stream reflects the company's ability to monetize its research and development pipeline through external commercialization efforts.